Form 4: Xenon Pharmaceuticals Director Steven Gannon Sells Shares

Director Steven Gannon of Xenon Pharmaceuticals Inc. (XENE) sold a total of 13,000 common shares on March 7, 2024, at prices ranging from $46.2012 to $46.45.

Summary

• On March 7, 2024, Steven Gannon, a director of Xenon Pharmaceuticals Inc., sold 13,000 common shares.
• The sales were executed in multiple transactions at varying prices.
• 1,000 shares were sold at $46.45 each.
• 5,000 shares were sold at $46.25 each.
• 5,000 shares were sold at a weighted average price of $46.3025.
• 2,000 shares were sold at a weighted average price of $46.2012.
• Following these transactions, Gannon directly owns 2,000 common shares.
• Gannon has granted a Power of Attorney to several individuals to handle SEC filings on his behalf.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to a director's stock sale. It doesn't inherently convey positive or negative sentiment, but the market's reaction to the sale could influence sentiment.

Industry Context

Sales of shares by company directors are a common occurrence and are closely watched by investors for signals about the company's prospects. It is important to consider the context of these sales, such as the director's overall holdings and any stated reasons for the transaction.

Stakeholder Impact

• Shareholders may react to the news of the director's stock sale, potentially impacting the stock price.
• The sale could be perceived as a lack of confidence in the company's future prospects, although it could also be for personal financial reasons.

Key Dates